MyBlueDotsAspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics MyBlueDots8 months ago01 mins VANCOUVER, British Columbia–(BUSINESS WIRE)– #biotech–Aspect Biosystems secures $115M Series B to advance bioprinted tissue therapeutics, accelerating development of functional cures for serious diseases Post navigation Previous: Resumen: Biocytogen y Acepodia combinan fuerzas para desarrollar anticuerpos biespecíficos y ADC de carga doble para el tratamiento de tumores complejosNext: NorthStar Medical Radioisotopes and YAP Therapeutics Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Products